| Market Capitalization (Millions $) |
1,688 |
| Shares
Outstanding (Millions) |
54 |
| Employees |
37 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-69 |
| Cash Flow (TTM) (Millions $) |
411 |
| Capital Exp. (TTM) (Millions $) |
0 |
Janux Therapeutics Inc
Janux Therapeutics Inc is a privately held biotechnology company that focuses on developing next-generation cancer immunotherapies. The company was founded in 2017 and is headquartered in San Diego, California.
Janux Therapeutics is committed to advancing cancer immunotherapy through the development of innovative drug candidates. The company's pipeline includes both small molecule drugs and biologics that have the potential to activate the immune system to target and destroy cancer cells.
The company's lead candidate, JAN101, is a small molecule drug that targets the tumor microenvironment. JAN101 is designed to selectively activate immune cells within the tumor microenvironment, leading to tumor regression and improved patient outcomes. The drug has demonstrated promising preclinical results in a range of cancer models and is currently in Phase 1 clinical trials.
Janux Therapeutics' pipeline also includes a number of next-generation biologics that utilize the company's proprietary Tumor Activated T Cell Engager (TRACT) platform. TRACT molecules are designed to selectively target and activate T cells within the tumor microenvironment, leading to improved tumor killing and reduced toxicity compared to traditional T cell-engaging therapies. The company is currently advancing several TRACT molecules through preclinical development.
In addition to its drug development programs, Janux Therapeutics has established a number of partnerships with leading pharmaceutical companies. The company has partnered with Merck to develop novel cancer immunotherapies using Janux's TRACT technology.
Janux Therapeutics' team includes experienced biotech executives, renowned scientists, and drug developers with a proven track record in developing novel cancer therapies. The company is backed by top-tier venture capital firms, including Polaris Partners, Avalon Ventures, and Section 3
Company Address: 10955 Vista Sorrento Parkway, Suite 200 San Diego 92130 CA
Company Phone Number: 751-4493 Stock Exchange / Ticker: NASDAQ JANX
|
1.92% 